ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1250

Can Patient-Reported Outcomes and Disease Activity Scores Predict Patient Acceptable Symptom State in Adult-Onset Still’s Disease?

Emre Bilgin 1, Timuçin Kaşifoğlu 2, Ahmet Omma 3, Cemal Bes 4, Muhammet Çınar 5, Hakan Emmungil 6, Orhan Küçükşahin 7, Servet Akar 8, Kenan Aksu 9, Fatih Yıldız 10, Nilüfer Kanıtez 11, Abdulsamet Erden 12, Sezin Turan 13, Ediz Dalkılıç 14, Selime Ermurat 15, Mutlu Hayran 16 and Umut Kalyoncu17, 1Hacettepe University Vasculitis Centre, Ankara, Turkey, Ankara, Turkey, 2Eskişehir Osmangazi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Eskişehir, Turkey, 3Ankara Numune Education and Research Hospital, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 4University of Medical Sciences, İstanbul, Turkey, 5University of Medical Sciences, Ankara, Turkey, 6Trakya University, Edirne, Turkey, 7Liv Hospital, Ankara, Turkey, 8Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, 9Ege University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, 10Kahramanmaraş Sütçü İmam University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Kahramanmaraş, Turkey, 11Koç University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, 12Ministry of Health Ankara City Hospital, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 13Trakya University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Edirne, Turkey, 14Uludağ University, Bursa, Turkey, 15Uludağ University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Bursa, Turkey, 16Hacettepe University, Faculty of Medicine, Department of Preventive Oncology, Ankara, Turkey, 17Hacettepe University Department of Rheumatology, Ankara, Turkey

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Adult-onset Still's disease, PASS and Disease Activity, patient-reported outcome measures

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: Miscellaneous Rheumatic & Inflammatory Disease Poster II: Autoinflammation Related Diseases & Therapies

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Adult-onset Still’s disease (AOSD) is a rare, chronic and auto-inflammatory disorder with multisystemic involvement. Patient Acceptable Symptom State (PASS) is the highest level of disease activity that patients feel quite well. Till now, there is no valid information for the possible cut-off values of patient-reported outcomes (PRO) or activity scores for AOSD patients to predict PASS. To determine cut-off values of PROs and activity scores to predict PASS in AOSD patients, we conducted this study.

Methods: We conducted a cross-sectional, multicenter study. All AOSD patients were fulfilled the Yamaguchi criteria. Still activity score (SAS) [1 point for neutrophilia ≥65%, 1 point for ferritin≥350 ng/ml, 2 point for fever and 2 point for arthralgia-additional 1 point if swollen joint number is equal or grater than 2], Pouchet’s systemic score (SS) [1 point for each of the following manifestation: fever, typical rash, pleuritis, pneumonia, pericarditis, hepatomegaly, or abnormal liver function tests, splenomegaly, lymphadenopathy, leukocytosis >15,000/mm2, sore throat, myalgia, and abdominal pain], visual analog scale (VAS) (0–10 cm) for physician’s (PhGA) and patient’s (PtGA) global assessment were used to determination of the disease activity. To assess PASS, we asked patients whether they would be okay or not, if the disease activity will be the same as now during the next month. Receiver operator curve (ROC) analysis was done to find cut-off values.

Results: Total of 72 (71% female) AOSD patients were enrolled. Mean age was 41 (13) years and median disease duration was 2 (0–30) years. Median SS and SAS were 3 (0-10) and 4 (0-7), respectively. Mean PtGA and PhGA were 4.29 (3.15) and 3.54 (3.07), respectively. Cross-sectional frequency of AOSD findings were as follow; fever 34 (47%), rash 27 (37.5%), arthritis 25 (34.7%), arthralgia 52 (72.2%), sore throat 30 (41.7), myalgia 38 (52.8), lymphadenopathy 13 (18.1%), splenomegaly 20 (27.8%), hepatomegaly 16 (22.2%), pleuritic pain 5 (6.9%), pericarditis 4 (5.6%), hemophagocytic syndrome 2 (2.8%). Mean (SD) ESR (mm/h), CRP (mg/dl), ferritin level and leukocyte count were 36.8 (34), 5.4 (7.3), 1758 (4070) and 9960 (4178), respectively. ROC analysis, area under curve, confidence intervals, sensitivity and specificity for different cut-off values were given in Table 1 and Figure 1.

Conclusion: In this study, all PROs and activity scores performed well to predict PASS. Still activity score seems to perform better over SS. To the best of our knowledge, this is the best study reporting cut-off values for PROs and activity scores to predict PASS.


PASS-Table1

Table 1. Sensitivity, specificity, AUC for several cut-off values of PROs and disease activity scores


PASS-figure1

Figure 1. ROC analysis for PROs and disease activity scores


Disclosure: E. Bilgin, None; T. Kaşifoğlu, None; A. Omma, None; C. Bes, None; M. Çınar, None; H. Emmungil, None; O. Küçükşahin, None; S. Akar, Abbvie, 2, 5, Amgen, 2, 5, MSD, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, 8, Roche, 2, 5, UCB, 2, 5; K. Aksu, None; F. Yıldız, None; N. Kanıtez, None; A. Erden, None; S. Turan, None; E. Dalkılıç, None; S. Ermurat, None; M. Hayran, None; U. Kalyoncu, UCB, 5.

To cite this abstract in AMA style:

Bilgin E, Kaşifoğlu T, Omma A, Bes C, Çınar M, Emmungil H, Küçükşahin O, Akar S, Aksu K, Yıldız F, Kanıtez N, Erden A, Turan S, Dalkılıç E, Ermurat S, Hayran M, Kalyoncu U. Can Patient-Reported Outcomes and Disease Activity Scores Predict Patient Acceptable Symptom State in Adult-Onset Still’s Disease? [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/can-patient-reported-outcomes-and-disease-activity-scores-predict-patient-acceptable-symptom-state-in-adult-onset-stills-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/can-patient-reported-outcomes-and-disease-activity-scores-predict-patient-acceptable-symptom-state-in-adult-onset-stills-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology